Pyoderma Gangrenosum

Suspect ulcerative PG when a papule, pustule, vesicle, or nodule evolves rapidly into a markedly painful ulcer with peripheral erythema, a violaceous undermined border, and progressive tissue loss. Anterior lower-leg involvement, multiple ulcers, cribriform healed scars, pathergy, inflammatory bowel disease (IBD), and inflammatory arthritis each increase diagnostic support. Wiley+2WileyClinical guidance of pyoderma gangrenosum 2022facsPyoderma Gangrenosum: A Diagnostic Challenge for the Surgical Consultant | ACSjbjsPostsurgical Pyoderma Gangrenosum After Minimally Invasive ...

Do not use morphology alone to justify immunosuppression. Vascular ulcers, antiphospholipid-associated ulcers, vasculitis, lymphoma, and deep fungal infection have been misdiagnosed as PG; one institutional reassessment found an alternative diagnosis in roughly 10% of patients initially labeled PG. NEJMNEJMPyoderma Gangrenosum Is a Diagnosis of Exclusion | NEJM Clinician The practical implication is to obtain tissue from an active ulcer edge and assess for infection before committing to systemic immunosuppression whenever the patient is clinically stable. Wiley+1WileyClinical guidance of pyoderma gangrenosum 2022jbjsPostsurgical Pyoderma Gangrenosum After Minimally Invasive ...

A rapidly advancing painful postoperative wound is a high-stakes branch point. Postsurgical PG can begin after an initially normal wound interval of 4 days to 6 weeks, then develop coalescing dehiscence and ulceration that extends beyond the operative field. It is commonly mistaken for pyogenic or necrotizing infection, and repeated debridement can accelerate necrosis through pathergy. Wolters Kluwer+2Wolters KluwerPyoderma gangrenosum: a case report highlighting... : International Journal of Surgery Case ReportsWolters KluwerSuccessful Treatment of Pyoderma Gangrenosum after... : Plastic and Reconstructive Surgery – Global OpenPubMedA Case of Pyoderma Gangrenosum Misdiagnosed as Necrotizing Infection: A Potential Diagnostic Catastrophe - PMC

Biopsy the active ulcer edge rather than only the necrotic center. In the 2018 Delphi framework for ulcerative PG, the major criterion is an ulcer-edge biopsy showing neutrophilic infiltrate. The framework is met by the major criterion plus at least 4 of 8 minor criteria. Wiley+1WileyClinical guidance of pyoderma gangrenosum 2022jbjsPostsurgical Pyoderma Gangrenosum After Minimally Invasive ... Histology also serves the essential exclusion function: it can help identify infection or other etiologies in an ulcer that clinically resembles PG. Wolters KluwerWolters KluwerSuccessful Treatment of Pyoderma Gangrenosum after... : Plastic and Reconstructive Surgery – Global Open

Score minor criteria deliberately: exclusion of infection; pathergy; personal history of IBD or inflammatory arthritis; a papule, pustule, or vesicle ulcerating within 4 days; peripheral erythema, an undermined border, and tenderness; multiple ulcers with at least one on an anterior lower leg; cribriform or wrinkled-paper scars; and reduction in ulcer size within 1 month after immunosuppressive treatment. Wiley+1WileyClinical guidance of pyoderma gangrenosum 2022jbjsPostsurgical Pyoderma Gangrenosum After Minimally Invasive ... In a validation described for this framework, the criteria had 86% sensitivity and 90% specificity against known cases and mimics. facsfacsPyoderma Gangrenosum: A Diagnostic Challenge for the Surgical Consultant | ACS

Interpret a nondiagnostic biopsy cautiously. Chronic ulcer histology may be nonspecific, and a multicenter retrospective report cited neutrophils in only 7% to 11% of PG biopsies; therefore, absent neutrophilic infiltrate should reopen the differential rather than automatically exclude a clinically compelling case. facultyadmin aadfacultyadmin aad[PDF] Therapeutic and Diagnostic Pearls-30' Mark Lebwohl, MD Conversely, a neutrophilic infiltrate does not replace microbiologic and clinicopathologic exclusion of infection and other mimics. Wiley+1WileyClinical guidance of pyoderma gangrenosum 2022facultyadmin aad[PDF] Therapeutic and Diagnostic Pearls-30' Mark Lebwohl, MD

For a single superficial or mild lesion, use local anti-inflammatory therapy: high-potency topical corticosteroid or a topical calcineurin inhibitor is described as first-line treatment. In a prospective cohort summarized in the literature, 44% of lesions healed by 6 months and 15% of those patients subsequently had recurrent lesions. PubMedPubMedA Case of Pyoderma Gangrenosum Misdiagnosed as Necrotizing Infection: A Potential Diagnostic Catastrophe - PMC This approach is best reserved for limited disease without rapid extension, extensive ulceration, or a need for rapid systemic control.

Escalate to systemic therapy for numerous ulcers or total ulcer area greater than 4 cm². Systemic corticosteroids and cyclosporine are established rapid-onset options for severe PG. PubMed+1PubMedA Case of Pyoderma Gangrenosum Misdiagnosed as Necrotizing Infection: A Potential Diagnostic Catastrophe - PMCPubMedPyoderma Gangrenosum: Treatment Options The reviewed evidence identifies prednisolone and cyclosporine as systemic agents with level 1B evidence, but specific regimen selection and dosing must be individualized because the cited material does not provide a standardized dose protocol. PubMedPubMedPyoderma Gangrenosum: Treatment Options

Pair anti-inflammatory treatment with nontraumatic local wound care and active pain management. Because pathergy can follow debridement, bandaging, surgery, and other local trauma, avoid aggressive mechanical manipulation during active progression. Oxford Academic+1Oxford AcademicThird European Evidence-based Consensus on Diagnosis and ...Wolters KluwerSuccessful Treatment of Pyoderma Gangrenosum after... : Plastic and Reconstructive Surgery – Global Open If reconstruction becomes necessary for a large defect, coordinate it after inflammatory control; no standard reconstructive approach exists for postsurgical PG. Wolters KluwerWolters KluwerPostsurgical Pyoderma Gangrenosum Requiring... : Plastic and Reconstructive Surgery - Global Open

Consider a biologic when PG is inadequately controlled with conventional systemic therapy, when steroid-sparing treatment is needed, or when a coexisting inflammatory disorder makes a shared therapeutic target advantageous. Infliximab is the biologic with the strongest controlled evidence: 5 mg/kg was superior to placebo in a randomized trial, with clinical benefit reported in 69% of patients by week 6. PubMed+1PubMedPyoderma gangrenosum: challenges and solutions - PMCPubMedPyoderma Gangrenosum: Treatment Options Another summary of the trial reported response at 2 weeks in 46% of infliximab-treated patients versus 21% with placebo. PubMedPubMedBiologics for the treatment of pyoderma gangrenosum in ulcerative colitis - PMC

For PG associated with IBD, anti-TNF treatment may benefit both skin and bowel disease. Infliximab and adalimumab have been reported as effective, whereas etanercept is not effective for IBD and should not be selected when control of IBD is also a treatment objective. PubMedPubMedPyoderma gangrenosum: challenges and solutions - PMC This distinction matters even if etanercept has case-based PG activity.

Balance potential benefit against safety. TNF-alpha inhibitors carry increased risk of serious infections that may lead to hospitalization or death; reported concerns with infliximab and adalimumab also include heart failure, infection, and malignancy. PubMed+1PubMedPyoderma Gangrenosum with Biological Agents Therapy: A Systematic Review - PMCPubMedPyoderma Gangrenosum: Treatment Options Before initiating a TNF inhibitor, ensure that the ulcer has been evaluated for infection and review contraindication-relevant comorbidity and concurrent immunosuppression.

At treatment initiation, record ulcer dimensions, number, location, border undermining, peripheral erythema, tenderness, drainage, and any new trauma-associated lesions. Reassess objectively within 1 month: reduction in ulcer size after immunosuppressive medication is a Delphi minor diagnostic criterion, whereas persistent expansion should prompt reassessment for infection, vascular or thrombotic disease, vasculitis, neoplasm, and continued pathergy. Wiley+2WileyClinical guidance of pyoderma gangrenosum 2022jbjsPostsurgical Pyoderma Gangrenosum After Minimally Invasive ...NEJMPyoderma Gangrenosum Is a Diagnosis of Exclusion | NEJM Clinician

Evaluate associated systemic disease because PG may coexist with IBD, inflammatory arthritis, hematologic malignancy, autoimmune disease, or inherited inflammatory syndromes. ScienceDirect+2ScienceDirectReconstructive microsurgical approach for the treatment of pyoderma gangrenosumPubMedManagement of Idiopathic Pyoderma Gangrenosum With Azathioprine As the Primary Adjunct in an Asian Man: A Case Report - PubMedPubMedA Case of Pyoderma Gangrenosum Misdiagnosed as Necrotizing Infection: A Potential Diagnostic Catastrophe - PMC Treating the associated disorder may hasten PG resolution, and selection of a systemic agent can be coordinated with the therapy required for the underlying condition. PubMed+1PubMedA Case of Pyoderma Gangrenosum Misdiagnosed as Necrotizing Infection: A Potential Diagnostic Catastrophe - PMCPubMedPyoderma gangrenosum: challenges and solutions - PMC

Expect healing to be slow even after inflammatory control. One surgical review cited average complete healing at 20.37 weeks. facsfacsPyoderma Gangrenosum: A Diagnostic Challenge for the Surgical Consultant | ACS Do not interpret delayed epithelial closure alone as failed immunosuppression if border activity and ulcer dimensions are improving; however, new ulceration after local trauma requires renewed attention to pathergy. Oxford Academic+1Oxford AcademicThird European Evidence-based Consensus on Diagnosis and ...Wolters KluwerSuccessful Treatment of Pyoderma Gangrenosum after... : Plastic and Reconstructive Surgery – Global Open